As reported by the Senate Committee on Finance on June 25, 2018
On June 25, 2018, the Senate Committee on Finance reported legislation related to the nation’s response to the opioid epidemic. Generally, S. 3120 would:
- Expand Medicare and Medicaid coverage of services to treat opioid use disorder;
- Give Medicare providers and health plans additional tools to curtail inappropriate prescribing and use of opioids;
- Require the completion of studies and reports related to various aspects of treatment programs funded under Medicare and Medicaid; and
- Support families struggling with opioid and other substance use disorders.
CBO estimates that enacting S. 3120 would reduce direct spending by $21 million over the 2019-2028 period. In addition, CBO estimates that implementing the bill would cost about $35 million over the same period, assuming appropriation of the necessary and specified amounts. Because enacting S. 3120 would affect direct spending, pay-as-you-go procedures apply. CBO estimates that enacting S. 3120 would not affect revenues.
CBO estimates that enacting S. 3120 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2029.
S. 3120 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act (UMRA).